REGN Regeneron Pharmaceuticals, Inc. logo

REGN Regeneron Pharmaceuticals, Inc.

Healthcare
$638.88-0.58%ClosedMarket Cap: $65.82B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

17.54

PEG

8.38

P/B

2.11

P/S

4.41

EV/EBITDA

11.41

DCF Value

$2,118.41

FCF Yield

6.3%

Div Yield

0.6%

Margins & Returns

Gross Margin

84.5%

Operating Margin

24.3%

Net Margin

29.6%

ROE

14.3%

ROA

10.8%

ROIC

8.5%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$3.61B$727.2M$
Q4 null$3.88B$844.6M$
FY null$14.34B$4.50B$
Q3 null$3.75B$1.46B$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$843.84

Target (Median)

$860.00

Target Range

$641.00 - $995.00

5 Strong Buy18 Buy8 Hold0 Sell0 Strong Sell
Canaccord GenuityBuy
2026-05-19
CitigroupNeutral
2026-05-18
Truist SecuritiesBuy
2026-05-18
JP MorganOverweight
2026-05-18
Wells FargoEqual Weight
2026-05-18

Trading Activity

Insider Trades

View All
RYAN ARTHUR Fdirector
SellMon May 04
RYAN ARTHUR Fdirector
SellMon May 04
RYAN ARTHUR Fdirector
SellMon May 04
RYAN ARTHUR Fdirector
SellMon May 04
RYAN ARTHUR Fdirector
SellMon May 04

Congress Trades

View All
Ro KhannaBuy
Wed May 13
Julia LetlowBuy
Fri Mar 13

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

Beta

0.30

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Peers